ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
A failed trial is a failed trial, says China’s regulator
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
